nctId: NCT06298006 id: 275025 briefTitle: A Two Year Longitudinal Clinical Study of Neurocognitive and Psychiatric Symptoms in Post COVID-19 Patients acronym: PASC24 overallStatus: RECRUITING date: 2022-02-22 date: 2026-12-31 date: 2027-06-30 date: 2024-03-07 date: 2024-03-07 name: Region Örebro County class: OTHER name: Örebro University, Sweden name: Karolinska Institutet name: Karolinska University Hospital name: Sahlgrenska University Hospital, Sweden briefSummary: The prospective, longitudinal, open observational study monitors patients with cognitive and neuropsychological symptoms after COVID-19 infection, in a longitudinal manner to see how the disease has affected their physical, psychological and cognitive function, their ability to be active, return to work, their health-related quality of life in correlation with potential diagnostic and prognostic markers. conditions: COVID-19 studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Follow-up measure: Change in cognitive functions measured with Mindmore and change in cognitive profile in Mindmore. measure: Symptom improvement in depression measure: Self-reported symptom improvement in depression measure: Grade of self-reported mental fatigue measure: Rate of self-reported symptoms suggestive of post-traumatic stress disorder (PTSD) measure: Grade of self-reported stress measure: Grade of self-reported cognitive failures in everyday life measure: Occurence of activity limitations and changes in health-related quality of life (QoL) measure: Grade of work incapacity/sick leave and time to return to work measure: Changes in body size measure: Waist size measure: Rate of peak expiratory flow (PEF) measure: Grade of physical exercise capacity measure: Concetration of Beta-Amyloid 42 in cerebrospinal fluid (CSF) as a CSF biomarker of neurodegeneration. measure: Beta Amyloid Ratio 42/40 in cerebrospinal fluid (CSF) as a CSF biomarker of neurodegeneration linked to Alzheimer's disease measure: Concentration of neurogranin in cerebrospinal fluid (CSF) as a CSF biomarker of neurodegeneration linked to Alzheimer's disease measure: Concentration of Tau (P-Tau) protein in cerebrospinal fluid (CSF) as a CSF biomarker of cortikal damage/neurodegeneration measure: Concentration of phosphorylated Tau (P-Tau) in cerebrospinal fluid (CSF) as a CSF biomarker of neurodegeneration/taupathy measure: Concentration of neurofilament light (NFL) in cerebrospinal fluid (CSF) as a CSF biomarker of neurodegeneration measure: Concentration of neurofilament light (NFL) in plasma as a blood biomarker of neurodegeneration measure: Occurence of APOE4 allele as biomarker of genetic predisposition to Alzheimer's disease and susceptibility to more severe course of COVID-19 infection measure: Brain volumes and signal abnormalities in white and gray matter measure: Changes in functional and structural brain connectivity measure: Changes in gut microbiome sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Geriatrics, University Hospital Örebro status: RECRUITING city: Örebro country: Sweden name: Yvonne Freund-Levi, MD, PhD role: CONTACT phone: +46 736841130 email: yvonne.freund@oru.se name: Zbigniew Dzialanski, MD role: SUB_INVESTIGATOR lat: 59.27412 lon: 15.2066 hasResults: False